-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – PMX-205 in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PMX-205 in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. PMX-205 in Parkinson's Disease Drug Details: PMX-205 (TDI0116) is under development for...
-
Product Insights
NewEpilepsy Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
Epilepsy Clinical Trial Report Overview A total of 3474 epilepsy clinical trials were conducted as of April 2024. The epilepsy clinical trial report provides a comprehensive understanding of the epilepsy clinical trial scenario across regions, and countries (G7 & E7), along with insights into the various phases, trial status, and end points status. The report also includes information about the sponsor types and the prominent sponsors associated with the trials. Key Regions ·      North America ·      Europe ·      Asia-Pacific ·      ...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emactuzumab in Brenner Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emactuzumab in Brenner Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emactuzumab in Brenner Tumor Drug Details: Emactuzumab (RG-7155, RO5509554) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Plogosertib in Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Plogosertib in Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Plogosertib in Leukemia Drug Details: Plogosertib is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanubrutinib in Refractory Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanubrutinib in Refractory Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zanubrutinib in Refractory Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Emrusolmin in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emrusolmin in Multiple System Atrophy (MSA or Shy-Drager Syndrome or Multi-System Degeneration) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emrusolmin in Multiple System...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Emrusolmin in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Emrusolmin in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Emrusolmin in Parkinson's Disease Drug Details: Emrusolmin (TEV-56286) is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – CD19/CD22 CAR-T in B-Cell Non-Hodgkin Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - CD19/CD22 CAR-T in B-Cell Non-Hodgkin Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. CD19/CD22 CAR-T in B-Cell Non-Hodgkin Lymphoma Drug Details: Gene...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – STAR-0602 in Epithelial Ovarian Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. STAR-0602 in Epithelial Ovarian Cancer Drug Details: STAR-0602 is under development for the treatment of...